Myriad Genetics
SALT LAKE CITY, Oct. 8, 2024 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a series of Announced ongoing research collaboration. Breast cancer residual disease (MRD) testing using Myriad’s Precise® MRD test.
Research cooperation includes:
A study to determine whether circulating tumor DNA (ctDNA) levels can predict the magnitude of response to pembrolizumab and hormone therapy in patients with HR-positive inflammatory breast cancer who did not achieve pathological complete response at the time of surgery. Led by Bora Lim, MD, at the University of Texas MD Anderson Cancer Center.
A study to assess whether ctDNA levels correlate with lymph node metastases in patients newly diagnosed with HR-positive breast cancer and, if so, how that correspondence can be used to support surgical decision-making. . The study was led by Anna Weiss, M.D., from American University. Rochester Medical Center.
Multicenter prospective MONITOR Breast Study to determine the association of ctDNA levels to both neoadjuvant and adjuvant therapy in patients with newly diagnosed breast cancer across all subtypes. The study will involve 650 patients and evaluate the prognostic potential of ctDNA and its lead time for early detection of recurrence prior to standard-of-care imaging.
JBCRG-C11, a prospective multicenter study evaluating maintenance of complete responses with trastuzumab deruxtecan (T-DXd) in patients with HER2-positive advanced or metastatic breast cancer and whether ctDNA can be used to optimally guide treatment. CREA) was carried out under the leadership of Mr. Yoichi. Dr. Naito of the National Cancer Center Hospital East.
The study, in partnership with Aptitude Health, will assess ctDNA levels in high-risk patients at diagnosis, during neoadjuvant therapy, and after surgery in a community oncology setting.
“Compared to many other types of cancer, which typically have high levels of ctDNA in the blood, ctDNA levels are often very low in breast cancer, making MRD testing difficult,” Myriad Dale Massey, Genetics’ Chief Scientific Officer. “Myriad’s Precise MRD test tracks up to 1,000 tumor-specific mutations identified through whole-genome sequencing, making it well suited to overcome this challenge. Our collaborative research efforts are an important step in advancing the clinical application of next-generation MRD tests for breast cancer treatment and monitoring.”
Myriad continues to develop the Precise MRD test to meet the needs of cancer patients, academic partners, and biopharmaceutical companies. Myriad has previously conducted research in metastatic breast cancer with researchers at Memorial Sloan Kettering Cancer Center, and a prospective pan-cancer study including breast cancer with researchers at Japan’s National Cancer Center Hospital East. has announced joint research with MRD.
story continues
About Myriad Precision MRD Testing
Myriad’s Precise MRD test is a tumor-informed whole genome sequencing (WGS)-based test that monitors hundreds to thousands of tumor-specific mutations. This allows for excellent sensitivity and quantification of circulating tumor DNA (ctDNA) in the blood of cancer patients. The Precise MRD test can be used to monitor ctDNA levels throughout the clinical care of cancer patients, starting immediately after diagnosis and continuing through treatment and monitoring. The Precise MRD test can be used in research conducted jointly by Myriad and academic or pharmaceutical researchers.
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to improving the health and well-being of everyone. Myriad develops and develops genetic tests to assess the risk of disease onset or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and reduce healthcare costs. We provide. For more information, please visit www.myriad.com.
Myriad Safe Harbor Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, which includes 650 patient participants, The company’s research collaborations include studies evaluating the Shortening the time to detect recurrence prior to standard-of-care imaging is an important step in advancing the clinical application of next-generation MRD tests to breast cancer treatment and monitoring, and the company’s Precise MRD test This indicates that it is suitable for overcoming certain symptoms. The MRD test tracks up to 1,000 tumor-specific mutations identified through whole-genome sequencing, thus solving the challenges faced by MRD tests. These “forward-looking statements” are management’s expectations about future events as of the date hereof, and represent management’s expectations about future events that may cause actual results, conditions or events to differ materially and adversely from those anticipated. It is subject to certain known and unknown risks and uncertainties. Such factors include the risks described in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K filed on February 28, 2024; Contains risk factor updates filed from time to time with the U.S. Securities and Exchange Commission. The company’s quarterly reports are on Form 10-Q and its current reports are on Form 8-K. Myriad undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. expressly disclaimed.
Investor contact information
matt scalo
(801) 584-3532
IR@myriad.com
media contact
glenn farrell
(385) 318-3718
PR@myriad.com
